Biogen | BIIB - Operating Expenses



Biogen reported $1.79B in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
AbbVie USD 9.71B 96M Jun/2025
Acadia Pharmaceuticals USD 232.19M 7.16M Jun/2025
ALKERMES USD 297.68M 4.96M Jun/2025
Amgen USD 6.52B 337M Jun/2025
Bayer EUR 10.73B 688M Jun/2025
Biogen USD 1.79B 326.1M Jun/2025
BioMarin Pharmaceutical USD 548.52M 27.27M Jun/2025
Bristol-Myers Squibb USD 8.5B 265M Jun/2025
Eli Lilly USD 8.54B 1.22B Jun/2025
Gilead Sciences USD 4.35B 80M Jun/2025
Incyte USD 904.7M 56.97M Jun/2025
Merck USD 9.44B 217M Jun/2025
Moderna USD 1.04B 113M Jun/2025
Neurocrine Biosciences USD 541.9M 7M Jun/2025
Novartis USD 9.97B 1.02B Jun/2025
Pfizer USD 11.62B 1.58B Jun/2025
PTC Therapeutics USD 213.73M 7.86M Jun/2025
Regeneron Pharmaceuticals USD 2.6B 159.1M Jun/2025
Sanofi EUR 9.02B 702M Jun/2025
Sanofi EUR 8.8B 2.03B Jun/2025
Sarepta Therapeutics USD 495.51M 549.73M Jun/2025
Teva Pharmaceutical Industries USD 3.28B 95M Jun/2025
Ultragenyx Pharmaceutical USD 274.38M 7.85M Jun/2025
United Therapeutics USD 521.7M 110.1M Jun/2025
Vertex Pharmaceuticals USD 1.81B 71.4M Jun/2025